Antimicrobial Susceptibility Testing Market Summary

The global antimicrobial susceptibility testing market size was estimated at USD 3.42 billion in 2022 and is projected to reach USD 5.08 billion by 2030, growing at a CAGR of 5.1% from 2023 to 2030. This moderate yet steady growth reflects the increasing clinical importance of accurately identifying effective antimicrobial therapies. The market expansion is primarily driven by the rising incidence of infectious diseases worldwide, which has heightened the need for reliable diagnostic tools. In addition, the growing adoption of personalized medicine has increased demand for tests that can determine the most effective antimicrobial treatment for individual patients. Favorable initiatives undertaken by government bodies to reduce the burden of infectious diseases, along with the escalating challenge of antimicrobial resistance, are further contributing to market growth.

The increasing prevalence of targeted diseases such as pneumonia and bloodstream infections caused by pathogens including E. coli, K. pneumoniae, P. aeruginosa, and others is significantly driving the adoption of antimicrobial susceptibility testing. These infections often require timely and precise treatment decisions, making AST essential for selecting appropriate antibiotics and improving patient outcomes. Furthermore, the rising number of research and development activities aimed at developing novel and more effective therapeutic options for infectious diseases is supporting the growing use of AST in drug development processes. Pharmaceutical and biotechnology companies increasingly rely on these tests to evaluate the efficacy of new antimicrobial agents and optimize treatment strategies.

Key Market Trends & Insights

• North America dominated the global antimicrobial susceptibility testing market with the largest revenue share of 46.3% in 2022. The region’s leadership is supported by advanced healthcare infrastructure, high awareness of antimicrobial resistance, strong research capabilities, and widespread adoption of diagnostic technologies.
• The antimicrobial susceptibility testing market in the United States led the North America market and held the largest revenue share in 2022. This can be attributed to the high prevalence of infectious diseases, robust funding for healthcare and research, and the presence of key market players in the country.
• By product, the manual tests segment led the market, holding the largest revenue share of 53.27% in 2022. Manual testing methods continue to be widely used due to their cost-effectiveness, reliability, and established presence in clinical laboratories.
• By application, the drug development segment is expected to grow at the fastest CAGR from 2023 to 2030. The increasing focus on developing new antimicrobial drugs to combat resistance is driving the demand for AST in this segment.
• By end use, the hospitals segment held the dominant position in the market in 2022. Hospitals remain the primary end users due to the high volume of infectious disease cases and the need for accurate, timely diagnostic testing.

Order a free sample PDF of the Antimicrobial Susceptibility Testing Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2022 Market Size: USD 3.42 Billion
• 2030 Projected Market Size: USD 5.08 Billion
• CAGR (2023-2030): 5.1%
• North America: Largest market in 2022

Key Companies & Market Share Insights

The antimicrobial susceptibility testing industry is moderately fragmented, with the presence of a few major players and local players holding the majority of the share. Major players are focusing on various strategies to improve market growth and gain a larger market share. For instance, in August 2022, bioMérieux received the U.S. FDA approval for its SPECIFIC REVEAL Rapid Antimicrobial Susceptibility Test System, which is expected to increase the adoption of rapid AST during the treatment of antimicrobial resistance diseases.

Key Players

• Bio-Rad Laboratories Inc.
• Merck & Co., Inc.
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• BD
• bioMérieux SA
• Creative Diagnostics
• Hi-Media Laboratories Pvt. Ltd.
• ELITechGroup
• Hoffmann-La Roche Ltd

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The antimicrobial susceptibility testing market is expanding steadily as healthcare systems address the rising burden of infectious diseases and antimicrobial resistance. Growing emphasis on personalized medicine, supportive government initiatives, and increased research activities are strengthening market demand. North America, led by the United States, continues to dominate due to strong healthcare and research infrastructure. The prominence of manual testing methods and hospital end users highlights the market’s clinical focus, while rapid growth in drug development applications reflects ongoing innovation. Overall, antimicrobial susceptibility testing remains a critical tool for effective infection management and improved patient outcomes.